Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Consumer Staples Select Sector SPDR Fund / Technical Analysis

<ul>
<li>Since late November we have been discussing our expectations for a pullback, while recommending shifting exposure to defensives (Staples, Utilities, Health Care) and/or taking profits.</li>
<li>The pullback is finally happening following breaks below 3910 support on the S&amp;P 500, $177.50 support on the Russell 2000 (IWM), and $279 support on the Nasdaq 100 (QQQ). </li>
<li>These levels are now resistance, while major resistance remains at 200-dayMAs/YTD downtrends. Stick with defensives/cash as we believe a test of the YTD lows on the aforementioned indexes is likely.</li>
</ul>


Since late November we have been discussing our expectations for a pullback, while recommending shifting exposure to defensives (Staples, Utilities, Health Care) and/or taking profits.
The pullback is finally happening following breaks below 3910 support on the S&amp;P 500, $177.50 support on the Russell 2000 (IWM), and $279 support on the Nasdaq 100 (QQQ). 
These levels are now resistance, while major resistance remains at 200-dayMAs/YTD downtrends. Stick with defensives/cash as we believe a test of the YTD lows on the aforementioned indexes is likely.


Upgrading Staples and Health Care to Overweight; Stay Defensive, Expecting Test of YTD Lows on SPX

<ul>
<li>Charts have not changed much from the prior week, with there actually being some deterioration within banks (KRE, KBE). </li>
<li>The $SPX has been unable to sustain a breakout above its 200-day MA/YTD downtrend, the $IWM remains below $190 resistance, and the DJIA could not sustain a breakout above 34,280</li>
<li>As long as these indexes are below these levels, we continue to see this as a good time to shift to more defensive areas and/or take profits.</li>
</ul>


Charts have not changed much from the prior week, with there actually being some deterioration within banks (KRE, KBE). 
The $SPX has been unable to sustain a breakout above its 200-day MA/YTD downtrend, the $IWM remains below $190 resistance, and the DJIA could not sustain a breakout above 34,280
As long as these indexes are below these levels, we continue to see this as a good time to shift to more defensive areas and/or take profits.


Failed Breakouts, Banks Crumbling -- Get Defensive; Buy Ideas Within Consumer Staples

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>This is our first report on global consumer goods giant, Unilever.</li><li>The company had a decent performance in 2021 and its growth continues to build in its first-half performance.</li><li>Unilever also uses its extensive market experience to deal with inflation.</li></ul>

This is our first report on global consumer goods giant, Unilever.The company had a decent performance in 2021 and its growth continues to build in its first-half performance.Unilever also uses its extensive market experience to deal with inflation.

Unilever ADR: Initiation of Coverage – Recent Strategic Shift

APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/farm-fresh-berhad" target="_blank" data-smartkarma-citation="entities:34617:1" rel="noopener">Farm Fresh Berhad (FF MY)</a> is looking to raise US$240m in its upcoming Malaysia IPO.</li>
<li>Farm Fresh Berhad is a dairy group that covers the entire value chain, from farming and manufacturing to distributing its various dairy products and plant-based products. </li>
<li>Farm Fresh’s extensive distribution network and  stockist/dealer channel has led to growing sales volume, which had in turn led to explosive revenue growth over the track period.</li>
</ul>



Farm Fresh Berhad (FF MY) is looking to raise US$240m in its upcoming Malaysia IPO.
Farm Fresh Berhad is a dairy group that covers the entire value chain, from farming and manufacturing to distributing its various dairy products and plant-based products. 
Farm Fresh’s extensive distribution network and  stockist/dealer channel has led to growing sales volume, which had in turn led to explosive revenue growth over the track period.


Farm Fresh Pre-IPO - Distribution Model Has Led to Strong Growth

Value Investing

Vladimir Dimitrov, CFA

<ul>
<li>Last year was a very challenging one for Unilever and the company significantly underperformed other consumer staples.</li>
<li>Exogenous factors, such as rising commodity inflation, are largely to blame for that performance.</li>
<li>Underneath the surface, however, Unilever now appears to be in a much better position than a year ago, while valuation remains conservative.</li>
</ul>


Last year was a very challenging one for Unilever and the company significantly underperformed other consumer staples.
Exogenous factors, such as rising commodity inflation, are largely to blame for that performance.
Underneath the surface, however, Unilever now appears to be in a much better position than a year ago, while valuation remains conservative.


Unilever: Short-Term Pain Continues And That Doesn't Bother Me

United Kingdom

Unilever PLC manufactures personal care products. The Company offers consumer goods, food, detergents, fragrances, beauty, home, and personal care products. Unilever serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Unilever (UL US)

Upgrading Staples and Health Care to Overweight; Stay Defensive, Expecting Test of YTD Lows on SPX

Since late November we have discussed our expectations for a pullback, recommending shifting exposure to defensives $XLP $XLV $XLU and/or taking...

Vermilion Research

Failed Breakouts, Banks Crumbling -- Get Defensive; Buy Ideas Within Consumer Staples

$SPX unable to sustain a breakout above 200-day MA/YTD downtrend, $IWM remains below $190 resistance, $DJI could not sustain a breakout above...

Vermilion Research

Unilever ADR: Initiation of Coverage – Recent Strategic Shift

This is our first report on global consumer goods giant, Unilever. The company had a decent performance in 2021 and its growth continues to build...

Baptista Research

Farm Fresh Pre-IPO - Distribution Model Has Led to Strong Growth

Farm Fresh Berhad (FF MY) is looking to raise US$240m in its upcoming Malaysia IPO. The dairy group covers the entire value chain and has a total...

Clarence Chu

Unilever: Short-Term Pain Continues And That Doesn't Bother Me

Last year was a very challenging one for Unilever and the company significantly underperformed other consumer staples. Exogenous factors, such as...

Vladimir Dimitrov, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)